SG10202110927VA - Process for the preparation of 4-phenyl-5-alkoxycarbonyl-2-thiazol-2-yl-1,4-dihydropyrimidin-6-yl]methyl]-3-oxo-5,6,8,8a-tetrahydro-1h-imidazo[1,5-a]pyrazin-2-yl]-carboxylic acid - Google Patents

Process for the preparation of 4-phenyl-5-alkoxycarbonyl-2-thiazol-2-yl-1,4-dihydropyrimidin-6-yl]methyl]-3-oxo-5,6,8,8a-tetrahydro-1h-imidazo[1,5-a]pyrazin-2-yl]-carboxylic acid

Info

Publication number
SG10202110927VA
SG10202110927VA SG10202110927VA SG10202110927VA SG10202110927VA SG 10202110927V A SG10202110927V A SG 10202110927VA SG 10202110927V A SG10202110927V A SG 10202110927VA SG 10202110927V A SG10202110927V A SG 10202110927VA SG 10202110927V A SG10202110927V A SG 10202110927VA
Authority
SG
Singapore
Prior art keywords
dihydropyrimidin
pyrazin
thiazol
imidazo
alkoxycarbonyl
Prior art date
Application number
SG10202110927VA
Other languages
English (en)
Inventor
Junli Chen
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of SG10202110927VA publication Critical patent/SG10202110927VA/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • A61P31/22Antivirals for DNA viruses for herpes viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
SG10202110927VA 2016-02-19 2017-02-16 Process for the preparation of 4-phenyl-5-alkoxycarbonyl-2-thiazol-2-yl-1,4-dihydropyrimidin-6-yl]methyl]-3-oxo-5,6,8,8a-tetrahydro-1h-imidazo[1,5-a]pyrazin-2-yl]-carboxylic acid SG10202110927VA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN2016074132 2016-02-19

Publications (1)

Publication Number Publication Date
SG10202110927VA true SG10202110927VA (en) 2021-11-29

Family

ID=58054130

Family Applications (2)

Application Number Title Priority Date Filing Date
SG11201805595TA SG11201805595TA (en) 2016-02-19 2017-02-16 Process for the preparation of 4-phenyl-5-alkoxycarbonyl-2-thiazol-2-yl-1,4-dihydropyrimidin-6-yl]methyl]-3-oxo-5,6,8,8a-tetrahydro-1h-imidazo[1,5-a]pyrazin-2-yl]-carboxylic acid
SG10202110927VA SG10202110927VA (en) 2016-02-19 2017-02-16 Process for the preparation of 4-phenyl-5-alkoxycarbonyl-2-thiazol-2-yl-1,4-dihydropyrimidin-6-yl]methyl]-3-oxo-5,6,8,8a-tetrahydro-1h-imidazo[1,5-a]pyrazin-2-yl]-carboxylic acid

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SG11201805595TA SG11201805595TA (en) 2016-02-19 2017-02-16 Process for the preparation of 4-phenyl-5-alkoxycarbonyl-2-thiazol-2-yl-1,4-dihydropyrimidin-6-yl]methyl]-3-oxo-5,6,8,8a-tetrahydro-1h-imidazo[1,5-a]pyrazin-2-yl]-carboxylic acid

Country Status (17)

Country Link
US (1) US10927116B2 (es)
EP (2) EP3954691A1 (es)
JP (1) JP6672471B2 (es)
KR (2) KR102255228B1 (es)
CN (1) CN108718527B (es)
AR (1) AR107633A1 (es)
AU (2) AU2017219189B2 (es)
BR (1) BR112018016932A2 (es)
CA (1) CA3011650A1 (es)
ES (1) ES2899369T3 (es)
HR (1) HRP20211816T1 (es)
IL (2) IL260153B (es)
MX (1) MX2018009944A (es)
PL (1) PL3416966T3 (es)
SG (2) SG11201805595TA (es)
SI (1) SI3416966T1 (es)
WO (1) WO2017140750A1 (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS58384B1 (sr) * 2014-03-07 2019-04-30 Hoffmann La Roche Novi 6-fuzionisani heteroarildihidropirimidini za lečenje i profilaksu infekcije virusom hepatitisa b
CA3068128A1 (en) 2017-06-26 2019-01-03 North & South Brother Pharmacy Investment Company Limited Dihydropyrimidine compounds and uses thereof in medicine
WO2019001420A1 (en) 2017-06-27 2019-01-03 Janssen Pharmaceutica Nv HETEROARYLDIHYDROPYRIMIDINE DERIVATIVES AND METHODS OF TREATING INFECTIONS WITH HEPATITIS B VIRUS
WO2019076310A1 (en) * 2017-10-18 2019-04-25 Sunshine Lake Pharma Co., Ltd. DIHYDROPYRIMIDINE COMPOUNDS AND USES THEREOF IN MEDICINE
TW201945003A (zh) 2018-03-01 2019-12-01 愛爾蘭商健生科學愛爾蘭無限公司 2,4-二胺基喹唑啉衍生物及其醫學用途
US11053235B2 (en) 2018-08-09 2021-07-06 Janssen Sciences Ireland Unlimited Company Substituted 1,4-dihydropyrimidines for the treatment of HBV infection or HBV-induced diseases
US20220048919A1 (en) * 2018-12-20 2022-02-17 Janssen Phrmaceutica NV Heteroaryldihydropyrimidine derivatives and methods of treating hepatitis b infections
TW202035412A (zh) * 2018-12-20 2020-10-01 比利時商健生藥品公司 雜芳基二氫嘧啶衍生物和治療b型肝炎感染之方法
MX2021011614A (es) * 2019-03-25 2021-10-13 Hoffmann La Roche Formas solidas de un compuesto del modificador alosterico de la proteina del nucleo del vhb.
US20220315588A1 (en) 2019-06-06 2022-10-06 Hoffmann-La Roche Inc. Alternative process for the preparation of 4-phenyl-5-alkoxycarbonyl-2-thiazol-2-yl-1,4-dihydropyrimidin-6-yl]methyl]-3-oxo-5,6,8,8a-tetrahydro-1h-imidazo[1,5-a]pyrazin-2-yl]-carboxylic acid
WO2020255039A1 (en) 2019-06-18 2020-12-24 Janssen Sciences Ireland Unlimited Company Combination of hepatitis b virus (hbv) vaccines and quinazoline derivatives
US20230083012A1 (en) * 2019-07-31 2023-03-16 Janssen Sciences Ireland Unlimited Company Dihydropyrimidine derivatives and uses thereof in the treatment of hbv infection or of hbv-induced diseases
CN112707910A (zh) * 2019-10-24 2021-04-27 广东东阳光药业有限公司 二氢嘧啶类化合物及其在药物中的应用
AU2021266084A1 (en) * 2020-04-28 2022-10-20 F. Hoffmann-La Roche Ag Process for the preparation of a chiral piperazine-2-carboxylic acid

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10012823A1 (de) 2000-03-16 2001-09-20 Bayer Ag Arzneimittel gegen virale Erkrankungen
DE10125131A1 (de) 2001-05-23 2002-12-05 Bayer Ag Verfahren zur Spaltung des Methyl 4-(2-chlor-4-fluorphenyl)-2-(3,5-difluor-2-pyridinyl)-6-methyl-1,4-dihydro-5-pyrmidincarboxylat-Racemats
CN100453542C (zh) 2007-04-30 2009-01-21 广东东阳光药业有限公司 2-杂环取代的二氢嘧啶消旋化合物的拆分方法
WO2010069147A1 (zh) 2008-12-17 2010-06-24 张中能 二氢嘧啶类化合物、其组合物及其应用
AU2013305390C1 (en) 2012-08-24 2015-12-24 Ruyuan Wei Xiang Technology Co., Ltd. Dihydropyrimidine compounds and their application in pharmaceuticals
SG11201500377UA (en) 2012-09-10 2015-02-27 Hoffmann La Roche 6-amino acid heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis b virus infection
AU2014267198A1 (en) 2013-05-17 2015-11-05 F. Hoffmann-La Roche Ag 6-bridged heteroaryldihydropyrimidines for the treatment and prophylaxis of Hepatitis B virus infection
RS58384B1 (sr) 2014-03-07 2019-04-30 Hoffmann La Roche Novi 6-fuzionisani heteroarildihidropirimidini za lečenje i profilaksu infekcije virusom hepatitisa b
WO2016016196A1 (en) * 2014-07-31 2016-02-04 F. Hoffmann-La Roche Ag Novel chiral resolution of 4-aryl-2-thiazol-2-yl-1,4-dihydropyrimidine-5-carboxylic acid esters
AR103222A1 (es) 2014-12-23 2017-04-26 Hoffmann La Roche Procedimiento para la preparación de análogos de 4-fenil-5-alcoxicarbonil-2-tiazol-2-il-1,4-dihidropirimidina

Also Published As

Publication number Publication date
JP6672471B2 (ja) 2020-03-25
BR112018016932A2 (pt) 2019-01-08
KR20210059801A (ko) 2021-05-25
AU2021203860A1 (en) 2021-07-08
US10927116B2 (en) 2021-02-23
IL260153B (en) 2021-10-31
CA3011650A1 (en) 2017-08-24
EP3416966A1 (en) 2018-12-26
WO2017140750A1 (en) 2017-08-24
IL286912A (en) 2021-10-31
JP2019507144A (ja) 2019-03-14
MX2018009944A (es) 2018-11-09
EP3416966B1 (en) 2021-09-29
KR20180104177A (ko) 2018-09-19
HRP20211816T1 (hr) 2022-03-04
US20190010155A1 (en) 2019-01-10
AU2017219189B2 (en) 2021-04-01
AR107633A1 (es) 2018-05-16
PL3416966T3 (pl) 2022-01-17
ES2899369T3 (es) 2022-03-11
SG11201805595TA (en) 2018-07-30
KR102255228B1 (ko) 2021-05-25
IL260153A (en) 2018-07-31
EP3954691A1 (en) 2022-02-16
CN108718527B (zh) 2022-06-28
CN108718527A (zh) 2018-10-30
AU2017219189A1 (en) 2018-06-28
SI3416966T1 (sl) 2022-01-31

Similar Documents

Publication Publication Date Title
IL286912A (en) Process for the preparation of 4-phenyl-5-alkoxycarbonyl-2-thiazol-2-yl-1,4-dihydropyrimidin-6-yl]methyl]-3-oxo-5,6,8,8a-tetrahydro-1h-imidazo[1,5-a]pyrazin-2-yl]-carboxylic acid
IL266170A (en) A process for the preparation of pyrazolo[1,5-a]pyrimidines and their salts
HK1245764A1 (zh) 3-取代的5-氨基-6h-噻唑並[4,5-d]嘧啶-2,7-二酮化合物
HRP20211261T8 (hr) [1,2,4]triazolo[1,5-a]piridinil supstituirani spojevi indola
ZA201605666B (en) Pyrazolo[1,5-a]pyrimidines as antiviral compounds
IL290419B (en) Imidazo[a-1,5]pyrazine derivatives as inhibitors of pi3k delta
HK1254651A1 (zh) 吡唑並[1,5-a]嘧啶-3-甲酰胺的環醚衍生物
ZA201804871B (en) Process for preparing 7h-pyrrolo [2, 3-d] pyrimidine compounds
EP3405456A4 (en) PROCESS FOR THE PREPARATION OF 4-ALKOXY-3-ACETOXYPICOLINIC ACIDS
EP3548457A4 (en) IMPROVED METHOD FOR PRODUCING 2,3,3,3-TETRAFLUORPROPEN
EP3422855A4 (en) PROCESS FOR THE PREPARATION OF 4-ALKOXY-3-HYDROXYPICOLIC ACIDS
EP3727377A4 (en) PROCESS FOR THE PREPARATION OF PYRIMIDINYL-4-AMINOPYRAZOLE COMPOUNDS
SG11202111538PA (en) Alternative process for the preparation of 4-phenyl-5-alkoxycarbonyl-2-thiazol-2-yl-1,4-dihydropyrimidin-6-yl]methyl]-3-oxo-5,6,8,8a-tetrahydro-1h-imidazo[1,5-a]pyrazin-2-yl]-carboxylic acid
EP3436439A4 (en) METHOD FOR PRODUCING DIPHENYLPYRAZINE DERIVATIVES
EP3405034A4 (en) PROCESS FOR THE PREPARATION OF 4-ALKOXY-3-HYDROXYPICOLIC ACIDS
IL267801A (en) Process for the preparation of 3-disubstituted 5-amino-h6-thiazolo[5,4-d]pyrimidine-7,2-dione compounds
PL3277687T3 (pl) Pochodne 7-(morfolin-4-ylo)pirazolo[1,5-a]pirymidyny użyteczne do leczenia chorób immunologicznych lub zapalnych lub nowotworów
EP3676272A4 (en) IXAZOMIB CITRATE PREPARATION PROCESS
AU2018297073A1 (en) Process for the preparation of morphinane compounds
IL250260A0 (en) Process for preparing 4,5,6-trichloropicolinic acid
IL274560A (en) A process for the preparation of raltagravir
HK1257427A1 (zh) 用於製備2-吡唑並[1,5-a]吡嗪-2-基吡啶並[1,2-a]嘧啶-4-酮的方法
ZA201702297B (en) A process for the preparation of 3-phenyl/heteroaryl-6-phenoxy-8-alkylamino-imidazo[1,2-b]pyridazine derivatives